WILKES NSG 552 EXAM 1
PSYCHOPHARMACOLOGY TEST BANK
QUESTIONS AND ANSWERS GUARANTEED
PASS
This comprehensive question psychopharmacology test
bank features authentic multiple-choice questions, accurate
answers, and detailed rationales tailored to curriculum
benchmarks. It delivers intensive preparation on
neurotransmitter pathways, mood stabilizer dynamics,
enzyme interactions, and safety monitoring protocols. It is
engineered as a premium, high-yielding resource to
maximize student exam outcomes and ensure a guaranteed
pass.
Question 1
A patient with schizophrenia is initiated on a high-potency typical
antipsychotic. Two days later, they present with an acute,
involuntary contraction of the neck muscles (torticollis) and
upward deviation of the eyes. Which pathway and receptor
mechanism is primarily responsible for this adverse effect?
A. Mesolimbic pathway; D2 receptor hypersensitivity
B. Nigrostriatal pathway; excessive D2 receptor blockade
C. Mesocortical pathway; 5-HT2A receptor antagonism
D. Tuberoinfundibular pathway; alpha-1 adrenergic blockade
Answer: B. Nigrostriatal pathway; excessive D2 receptor blockade
,Rationale: Acute dystonic reactions result from high levels of
dopamine D2 receptor blockade within the motor-controlling
nigrostriatal pathway. High-potency typical antipsychotics
have a strong affinity for these receptors, which creates an
abrupt deficit in dopamine signaling relative to acetylcholine,
precipitating acute muscle spasms.
Question 2
How do second-generation (atypical) antipsychotics significantly
reduce the liability for extrapyramidal symptoms (EPS) in the
nigrostriatal tract compared to first-generation antipsychotics?
A. By acting as potent full agonists at presynaptic D2 receptors
B. By selectively blocking M1 muscarinic receptors over all
dopamine receptors
C. By combining dopamine D2 receptor antagonism with 5-HT2A
serotonin receptor antagonism
D. By irreversibly binding to post-synaptic D4 receptors in the
striatum
Answer: C. By combining dopamine D2 receptor antagonism with
5-HT2A serotonin receptor antagonism
Rationale: Serotonin normally acts via 5-HT2A receptors to
inhibit dopamine release in the striatum. By blocking 5-HT2A
receptors, atypical antipsychotics disinhibit (increase)
dopamine release in the nigrostriatal pathway. This localized
increase in dopamine competes with the antipsychotic for D2
receptors, mitigating excessive motor blockade and lowering
EPS risk.
Question 3
A 34-year-old patient treated for schizophrenia is noted to have
significant weight gain, a new fasting plasma glucose level of 132
,mg/dL, and elevated triglycerides after 12 weeks of treatment.
Which pair of antipsychotic medications carries the highest risk for
this metabolic profile?
A. Aripiprazole and Ziprasidone
B. Clozapine and Olanzapine
C. Lurasidone and Haloperidol
D. Risperidone and Asenapine
Answer: B. Clozapine and Olanzapine
Rationale: Clozapine and olanzapine possess the highest
propensity for inducing profound metabolic syndrome,
including severe weight gain, insulin resistance,
dyslipidemia, and new-onset Type 2 diabetes. This liability is
heavily linked to their high-affinity antagonism at histamine
H1 and serotonin 5-HT2C receptors.
Question 4
A patient stabilized on Olanzapine 15 mg daily for the past year
decided to quit their 1.5 pack-per-day cigarette smoking habit one
week ago. They present to the clinic reporting severe sedation
and cognitive slowing. What is the pharmacokinetic explanation
for this change?
A. Cigarette smoke contains nicotine which permanently destroys
CYP2D6 enzymes
B. Polycyclic aromatic hydrocarbons in tobacco smoke induce
CYP1A2; quitting removes this induction, causing olanzapine
levels to rise
C. Nicotine directly competes with olanzapine for plasma protein
binding sites
D. Quitting smoking drastically reduces renal blood flow,
preventing drug clearance
, Answer: B. Polycyclic aromatic hydrocarbons in tobacco smoke
induce CYP1A2; quitting removes this induction, causing
olanzapine levels to rise
Rationale: The polycyclic aromatic hydrocarbons in tobacco
smoke—not the nicotine—are potent inducers of the hepatic
enzyme CYP1A2, which is primary in olanzapine metabolism.
When a patient abruptly stops smoking, the enzymatic
induction fades, metabolic clearance drops, and serum levels
of olanzapine elevate significantly, resulting in toxicity and
increased sedation.
Question 5
According to the Clozapine Risk Evaluation and Mitigation
Strategy (REMS) protocol, what is the absolute minimum Absolute
Neutrophil Count (ANC) threshold required to safely initiate
outpatient clozapine therapy in a patient with a standard
hematologic profile?
A. Greater than or equal to 2,000/µL
B. Greater than or equal to 1,500/µL
C. Greater than or equal to 1,000/µL
D. Greater than or equal to 500/µL
Answer: B. Greater than or equal to 1,500/µL
Rationale: For patients without Benign Ethnic Neutropenia
(BEN), a baseline ANC must be greater than or equal to
1,500/µL to safely initiate clozapine treatment. This strict
monitoring infrastructure is crucial due to clozapine's
documented idiosyncratic risk of causing life-threatening
agranulocytosis.
Question 6
PSYCHOPHARMACOLOGY TEST BANK
QUESTIONS AND ANSWERS GUARANTEED
PASS
This comprehensive question psychopharmacology test
bank features authentic multiple-choice questions, accurate
answers, and detailed rationales tailored to curriculum
benchmarks. It delivers intensive preparation on
neurotransmitter pathways, mood stabilizer dynamics,
enzyme interactions, and safety monitoring protocols. It is
engineered as a premium, high-yielding resource to
maximize student exam outcomes and ensure a guaranteed
pass.
Question 1
A patient with schizophrenia is initiated on a high-potency typical
antipsychotic. Two days later, they present with an acute,
involuntary contraction of the neck muscles (torticollis) and
upward deviation of the eyes. Which pathway and receptor
mechanism is primarily responsible for this adverse effect?
A. Mesolimbic pathway; D2 receptor hypersensitivity
B. Nigrostriatal pathway; excessive D2 receptor blockade
C. Mesocortical pathway; 5-HT2A receptor antagonism
D. Tuberoinfundibular pathway; alpha-1 adrenergic blockade
Answer: B. Nigrostriatal pathway; excessive D2 receptor blockade
,Rationale: Acute dystonic reactions result from high levels of
dopamine D2 receptor blockade within the motor-controlling
nigrostriatal pathway. High-potency typical antipsychotics
have a strong affinity for these receptors, which creates an
abrupt deficit in dopamine signaling relative to acetylcholine,
precipitating acute muscle spasms.
Question 2
How do second-generation (atypical) antipsychotics significantly
reduce the liability for extrapyramidal symptoms (EPS) in the
nigrostriatal tract compared to first-generation antipsychotics?
A. By acting as potent full agonists at presynaptic D2 receptors
B. By selectively blocking M1 muscarinic receptors over all
dopamine receptors
C. By combining dopamine D2 receptor antagonism with 5-HT2A
serotonin receptor antagonism
D. By irreversibly binding to post-synaptic D4 receptors in the
striatum
Answer: C. By combining dopamine D2 receptor antagonism with
5-HT2A serotonin receptor antagonism
Rationale: Serotonin normally acts via 5-HT2A receptors to
inhibit dopamine release in the striatum. By blocking 5-HT2A
receptors, atypical antipsychotics disinhibit (increase)
dopamine release in the nigrostriatal pathway. This localized
increase in dopamine competes with the antipsychotic for D2
receptors, mitigating excessive motor blockade and lowering
EPS risk.
Question 3
A 34-year-old patient treated for schizophrenia is noted to have
significant weight gain, a new fasting plasma glucose level of 132
,mg/dL, and elevated triglycerides after 12 weeks of treatment.
Which pair of antipsychotic medications carries the highest risk for
this metabolic profile?
A. Aripiprazole and Ziprasidone
B. Clozapine and Olanzapine
C. Lurasidone and Haloperidol
D. Risperidone and Asenapine
Answer: B. Clozapine and Olanzapine
Rationale: Clozapine and olanzapine possess the highest
propensity for inducing profound metabolic syndrome,
including severe weight gain, insulin resistance,
dyslipidemia, and new-onset Type 2 diabetes. This liability is
heavily linked to their high-affinity antagonism at histamine
H1 and serotonin 5-HT2C receptors.
Question 4
A patient stabilized on Olanzapine 15 mg daily for the past year
decided to quit their 1.5 pack-per-day cigarette smoking habit one
week ago. They present to the clinic reporting severe sedation
and cognitive slowing. What is the pharmacokinetic explanation
for this change?
A. Cigarette smoke contains nicotine which permanently destroys
CYP2D6 enzymes
B. Polycyclic aromatic hydrocarbons in tobacco smoke induce
CYP1A2; quitting removes this induction, causing olanzapine
levels to rise
C. Nicotine directly competes with olanzapine for plasma protein
binding sites
D. Quitting smoking drastically reduces renal blood flow,
preventing drug clearance
, Answer: B. Polycyclic aromatic hydrocarbons in tobacco smoke
induce CYP1A2; quitting removes this induction, causing
olanzapine levels to rise
Rationale: The polycyclic aromatic hydrocarbons in tobacco
smoke—not the nicotine—are potent inducers of the hepatic
enzyme CYP1A2, which is primary in olanzapine metabolism.
When a patient abruptly stops smoking, the enzymatic
induction fades, metabolic clearance drops, and serum levels
of olanzapine elevate significantly, resulting in toxicity and
increased sedation.
Question 5
According to the Clozapine Risk Evaluation and Mitigation
Strategy (REMS) protocol, what is the absolute minimum Absolute
Neutrophil Count (ANC) threshold required to safely initiate
outpatient clozapine therapy in a patient with a standard
hematologic profile?
A. Greater than or equal to 2,000/µL
B. Greater than or equal to 1,500/µL
C. Greater than or equal to 1,000/µL
D. Greater than or equal to 500/µL
Answer: B. Greater than or equal to 1,500/µL
Rationale: For patients without Benign Ethnic Neutropenia
(BEN), a baseline ANC must be greater than or equal to
1,500/µL to safely initiate clozapine treatment. This strict
monitoring infrastructure is crucial due to clozapine's
documented idiosyncratic risk of causing life-threatening
agranulocytosis.
Question 6
